Pranay Dey

Passionately curious and hard-working PhD-SRF with strong history of advancing intellectual knowledge in the field of breast cancer. Prepared to leverage Bio-informatics, Structural Biology and Molecular Biology knowledge and 7 years of research experience to lead and answer any conundrum, within the limits of practicality. Analytical and Self-driven Research Fellow comfortable in designing, conducting and sharing results of complex and multi-faceted research. Awarded international travel grants to present work at International academic conferences. Collaborated with esteemed faculty and students to achieve excellence in preparation and performing tricky biological experiments.

Publication:

• P. Dey, M. Joshi, A. Mujawar, R. Malhotra, and A. De, “Direct knockdown of phospho-PTM targets mediated by TRIM21 can improve personalized treatment in breast cancer,” Cellular Oncology 2022, pp. 1–19, Jul. 2022, doi: 10.1007/S13402-022-00693-6. (publication from thesis).
• Dey P, Gadewal N, De A. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer. Int J Biol Macromol. 2023 May 6; 242(Pt 2):124765. doi: 10.1016/j.ijbiomac.2023.124765. Epub ahead of print. PMID: 37156315. (publication from thesis).
• A. Mal, P. Dey, R. M. Hayes, J. V. McCarthy, A. Ray, and A. De, “In Silico Identification of Potential Phosphorylation in the Cytoplasmic Domain of Epithelial Cell Adhesion Molecule,” ACS Omega, vol. 5, no. 48, pp. 30808–30816, Dec. 2020, doi: 10.1021/ACSOMEGA.0C02113/ASSET/IMAGES/LARGE/AO0C02113_0006.JPEG.
• Dey, P., Rathod, M., De, A. (2019). Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med. Press) 11, 115–135. doi: 10.2147/BCTT.S189224.
• Pranay Dey, Aniketh Bishnu, Renu Malhotra, Nikhil Gadewal, Pritha Ray and Abhijit De, HER2 hotspot dimerization domain mutations cause structural instability and signalling switch, leading to treatment failure in breast cancer. (manuscript under preparation) (publication from thesis).
• Mansi Joshi, Pranay Dey, and Abhijit De, “Recent advancements in direct protein knockdown technologies- emerging paradigms for targeted therapy,” ETAT (manuscript under review).
• Pratham Phadte, Megha Mehrotra, Aniketh Bishnu, Pranay Dey, Abhijit De, Bharat Rekhi and Pritha Ray, “The turnover of ID1 through autophagy dictates chemoresistance in Ovarian Cancer Stem Cells,” (manuscript under preparation).
• Mansi Joshi, Pranay Dey, Shalini Dimri and Abhijit De “FDA-approved Neratinib can be repurposed for TNBC cell and tumor growth by suppressing EGFR-ERK-STAT3 signaling cascade,” (manuscript under preparation).




Awards:

EACR 2022 Bursary Award to attend EACR congress 2022 in Seville, Spain

HBNI International travel grant 2022

Sam mistri International travel fellowship 2022

AIR-1 in ACTREC entrance exam and AIR-35 in CSIR-NET December 2017

AIR-2 in PGIMER entrance exam 2015